TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03796598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fecal Microbial transplant Capsules
Description: Oral capsules of FMT

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fecal Microbial transplant Capsules
Description: Oral capsules of FMT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fecal Microbial Transplant Enema
Description: FMT enema

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fecal Microbial Transplant Enema
Description: FMT enema

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04192539

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Taurine
Description: Serum taurine was determined by High Performance Liquid Chromatography (HPLC) according to the pre-column extraction and derivatization methodology of McMahon et al. In the present work, we use Shimadzu HPLC model LC-10AT

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Taurine
Description: Serum taurine was determined by High Performance Liquid Chromatography (HPLC) according to the pre-column extraction and derivatization methodology of McMahon et al. In the present work, we use Shimadzu HPLC model LC-10AT

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Taurine
Description: Serum taurine was determined by High Performance Liquid Chromatography (HPLC) according to the pre-column extraction and derivatization methodology of McMahon et al. In the present work, we use Shimadzu HPLC model LC-10AT

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Taurine
Description: Serum taurine was determined by High Performance Liquid Chromatography (HPLC) according to the pre-column extraction and derivatization methodology of McMahon et al. In the present work, we use Shimadzu HPLC model LC-10AT
Study: NCT00876499

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: A total of 8 questionnaires regarding fatigue taking approximately 30 minutes each, given before radiation therapy, weekly during, and after completion.
Study: NCT01149876

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nu Skin Product
Description: Thin layer of Nu Skin product applied to face.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nu Skin Product
Description: Thin layer of Nu Skin product applied to face.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cosmetic instrument
Description: Cosmetic instrument with topical Nu Skin product. Thin layer of Nu Skin product applied to face followed by galvanic, used for 3 minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tretinoin cream 0.05
Description: Thin layer of tretinoin applied to face.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: CeraVe moisturizer
Description: Thin layer of CeraVe applied to face.
Study: NCT02675218

Intervention type: OTHER
Intervention: Patients with rheumatoid arthritis
Description: Doppler effect at 3 months after Abatacept treatment initiation.
Study: NCT04400799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin 40Mg/0.4Ml Inj Syringe 0.4Ml
Description: daily incetion s.c. for 14 days
Study: NCT01510132

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost/timolol fixed combination (Travacom)
Description: Commercially-marketed drug for the treatment of open-angle glaucoma or ocular hypertension
Study: NCT04303546

Intervention type: DEVICE
Intervention: arterial stiffness measurements
Description: We will measure arterial stiffness by VOPITB and with others devices to validate VOPITB

Intervention type: DEVICE
Intervention: arterial stiffness measurements
Description: We will measure arterial stiffness by VOPITB and with others devices to validate VOPITB

Intervention type: DEVICE
Intervention: arterial stiffness measurements
Description: We will measure arterial stiffness by VOPITB and with others devices to validate VOPITB
Study: NCT03895697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasiglucagon
Description: Glucagon analogue

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasiglucagon
Description: Glucagon analogue
Study: NCT03745586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Day 3: Tocilizumab infusion (8mg/kg body-weight) Day 10- week 52: Tocilizumab s.c. injections (162mg) in weekly intervals

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucocorticoids
Description: Day0-day2: methylprednisolone 500mg i.v.
Study: NCT04137861

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bioceramics
Description: root repair material

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bioceramics
Description: root repair material
Study: NCT00269841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab 10 mg/kg
Description: Infliximab (anti-TNF chimeric monoclonal antibody \[cA2\]) 10 milligram per kilogram (mg/kg) will be administered as infusion at Week 0, 2 and 6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab 5 mg/kg
Description: Infliximab (anti-TNF chimeric monoclonal antibody \[cA2\]) 5 mg/kg will be administered as infusion at Week 0, 2 and 6.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be adminstered at Week 0, 2 and 6.
Study: NCT00988117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivastigmine Patch 9.5 cm2
Description: Subjects will be started on a 5cm2/24hr rivastigmine patch. After 4 weeks, the dose will be increased to a recommended target dose of 9.5cm2/24hr patch for 8 additional weeks.
Study: NCT02854397

Intervention type: OTHER
Intervention: blood sample

Intervention type: OTHER
Intervention: blood sample

Intervention type: OTHER
Intervention: blood sample
Study: NCT03809286

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active rTMS
Description: rTMS delivers magnetic stimulation to the brain by using an electromagnet to generate a current that can penetrate the scalp and skull.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Inpatient admission
Description: All subjects will be admitted to the hospital for a brief detoxification period followed by 3 weeks of abstinence.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Inpatient admission
Description: All subjects will be admitted to the hospital for a brief detoxification period followed by 3 weeks of abstinence.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham rTMS
Description: The sham coil setting is designed to mimic the auditory artifact and the scalp sensations evoked by the real coil, and to produce activation of facial muscles similar to the effect of a real H coil, without stimulating the brain itself.
Study: NCT01684111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBF 1120
Description: 2 x 150 mg capsules, oral, daily (Start dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: 25 mg/m2 i.v. on day 1 and 8 (three-week cycle)
Study: NCT01993628

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rey figure test

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rey figure test

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI
Study: NCT02180347

Intervention type: DEVICE
Intervention: Contact lenses

Intervention type: DEVICE
Intervention: Contact lenses
Study: NCT03557242

Intervention type: DEVICE
Group type: OTHER
Intervention: TAVR
Description: Transcatheter Aortic Valve Replacement

Intervention type: DEVICE
Group type: OTHER
Intervention: TAVR
Description: Transcatheter Aortic Valve Replacement

Intervention type: DEVICE
Group type: OTHER
Intervention: TAVR
Description: Transcatheter Aortic Valve Replacement

Intervention type: OTHER
Group type: OTHER
Intervention: Warfarin plus Aspirin
Description: Subjects randomized to this arm will receive Warfarin plus aspirin for 30- 45 days post TAVR

Intervention type: OTHER
Group type: OTHER
Intervention: Aspirin Only
Description: Subjects randomized to this arm will receive aspirin only post TAVR
Study: NCT03115671

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vayarin
Description: Vayarin capsule
Study: NCT03769077

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exergaming
Description: This study involves the use of multiplayer exercise video games or 'exergames' that incorporate an avatar powered by pedaling a recumbent stationary bicycle. The Liberi suite of exergames contains six mini-games, including a combination of cooperative games, competitive games and individual games designed to be fast-paced, action-oriented, and enjoyable for youth with special needs.
Study: NCT01044901

Intervention type: PROCEDURE
Intervention: MRI, Transthoracic Echocardiography, tonometry, EKG
Description: Unless contraindicated, subjects will receive Regadenoson and Gadolinium contrast agent during the Cardiac magnetic resonance. The tonometer, EKG, and echo are non-invasive procedures.

Intervention type: PROCEDURE
Intervention: MRI, Transthoracic Echocardiography, tonometry, EKG
Description: Unless contraindicated, subjects will receive Regadenoson and Gadolinium contrast agent during the Cardiac magnetic resonance. The tonometer, EKG, and echo are non-invasive procedures.
Study: NCT00185796

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total Lymphoid Irradiation (TLI)
Description: TLI is administered ten times in 120cGy fractions on day -11 through day -7 and day -4 through day -1

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anti-Thymocyte Globulin as Conditioning (ATG)
Description: Thymoglobulin will be administered five times intravenously at 1.5 mg/kg/day from day -11 through day -7 for a total dose of 7.5 mg/kg. Thymoglobulin doses will be based on the adjusted ideal body weight if the patient is greater than or equal to 15 kg over ideal body weight.
Study: NCT02565888

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daclatasvir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atazanavir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ritonavir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobicistat
Study: NCT03561025

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: 18F-FDG-PET/MRI
Description: Contrast-enhanced MRI scanning after injection of 18F-FDG

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 18F-FDG-PET/MRI
Description: Contrast-enhanced MRI scanning after injection of 18F-FDG

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: 18F-GE180-PET/MRI
Description: Contrast-enhanced MRI scanning after injection of 18F-GE180
Study: NCT00006220

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tretinoin
Study: NCT03216603

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health literacy intervention group
Description: In the health literacy intervention group all patients will receive self-management help using a motivating interviewing (MI) technique delivered by two MI and COPD trained nurses once a week for eight weeks after hospitalization. Subsequently, the contact between the patients and the nurses will be by follow up motivational telephone calls once a month or more if needed for four months (i.a a total of six months intervention period).
Study: NCT03561025

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 18F-GE180-PET/MRI
Description: Contrast-enhanced MRI scanning after injection of 18F-GE180
Study: NCT02956278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Allopurinol

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: lactose placebo pill

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: lactose placebo pill

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: lactose placebo pill
Study: NCT02782208

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acipimox
Description: Acipimox is administered 4 times previous to and during the investigation day. Acipimox is used to suppress the lipolytic effect of GH.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acipimox
Description: Acipimox is administered 4 times previous to and during the investigation day. Acipimox is used to suppress the lipolytic effect of GH.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is administered 4 times previous to and during the investigation day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is administered 4 times previous to and during the investigation day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GH substitution
Description: GH substitution as usually

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GH substitution
Description: GH substitution as usually
Study: NCT03080480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Pioglitazone is PPARγ agonist that may be enhance ROS production and partially restore host phagocytes in CGD.~pioglitazone is administered at a starting dose of 1 mg/kg and given the absence of adverse effects is progressively increased up to 3 mg/kg or 30 mg/daily.
Study: NCT03743480

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: early palliative care
Description: experimental arm. Patients in this arm will meet with the palliative care team soon after the decision on their last active treatment
Study: NCT03760458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC) Dispersible Tablets
Description: Fixed-dose combination dispersible tablets containing 60 mg ABC, 5 mg DTG, and 30 mg 3TC; administered orally once daily with or without food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC) Dispersible Tablets
Description: Fixed-dose combination dispersible tablets containing 60 mg ABC, 5 mg DTG, and 30 mg 3TC; administered orally once daily with or without food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC) Dispersible Tablets
Description: Fixed-dose combination dispersible tablets containing 60 mg ABC, 5 mg DTG, and 30 mg 3TC; administered orally once daily with or without food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC) Dispersible Tablets
Description: Fixed-dose combination dispersible tablets containing 60 mg ABC, 5 mg DTG, and 30 mg 3TC; administered orally once daily with or without food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC) Immediate Release Tablets (Immediate release)
Description: Fixed-dose combination immediate release tablets containing 600 mg ABC, 50 mg DTG, and 300 mg 3TC; administered orally once daily with or without food
Study: NCT02782208

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: GH pause
Description: GH substitution pause two days prior to the experimental day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: GH pause
Description: GH substitution pause two days prior to the experimental day
Study: NCT01072981

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HyperAcute-Pancreas Immunotherapy
Description: Up to 18 immunizations of 300 million immunotherapy cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m2/day once a week for 3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m2/day once a week for 3 weeks

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 5FU Chemoradiation
Description: 5FU 200-250 mg/m2/day over 5 1/2 weeks with radiation.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 5FU Chemoradiation
Description: 5FU 200-250 mg/m2/day over 5 1/2 weeks with radiation.
Study: NCT03777111

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Single Task Training: Single task training includes exercises that require only one task or stimulation. For this study the task consists of motor tasks (walking or balance) Dual Task Training: Dual task training includes exercises simultaneous performance of two tasks that can be performed independently, measured separately and with different goals. In the study motor tasks will combine with cognitive tasks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Single Task Training: Single task training includes exercises that require only one task or stimulation. For this study the task consists of motor tasks (walking or balance) Dual Task Training: Dual task training includes exercises simultaneous performance of two tasks that can be performed independently, measured separately and with different goals. In the study motor tasks will combine with cognitive tasks.
Study: NCT01249833

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oseltamivir
Description: Oseltamivir 75mg BID for 5 days
Study: NCT02203162

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electronic cigarette exposure
Description: 30 puffs of a disposable electronic cigarette, 30 seconds apart.
Study: NCT00989898

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Automated closed-loop insulin delivery
Description: Insulin infusion rates via the insulin pump will be dictated by a computer-based control algorithm according to the CGM glucose readings and automatically adjusted on the pump.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Automated closed-loop insulin delivery
Description: Insulin infusion rates via the insulin pump will be dictated by a computer-based control algorithm according to the CGM glucose readings and automatically adjusted on the pump.
Study: NCT03834155

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hospital-based CR + Movn Application
Description: Participants will be randomly assigned to a group that will receive hospital-based CR and access to the Movn mobile application.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Choice of Hospital or home-based CR + Movn Application
Description: Participants will be randomly assigned to a group that has opportunity to opt in to hospital-based cardiovascular rehabilitation or home-based cardiovascular rehabilitation. All will have access to the Movn Application.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hospital-based CR + Movn Application + Nudge
Description: Participants will be randomly assigned to a group that will receive hospital-based CR and access to the Movn mobile application, plus encouraging nudge messages.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Choice of Hospital or home-based CR + Movn Application + Nudge
Description: Participants will be randomly assigned to a group that has opportunity to opt in to hospital-based cardiovascular rehabilitation or home-based cardiovascular rehabilitation. All will have access to the Movn Application, plus encouraging nudge messages.
Study: NCT00092521

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V501
Description: Final Manufactured Product (FMP) quadrivalent HPV vaccine, a 0.5 mL intramuscular injection given at Day 1, Month 2 and Month 6.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: a 0.5 mL intramuscular placebo injection given at Day 1, Month 2 and Month 6.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Papillomavirus (HPV) 16 Monovalent
Description: HPV 16 Monovalent vaccine, a 0.5 mL intramuscular injection given at Day 1, Month 2 and Month 6.
Study: NCT02239081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTP-730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTP-730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTP-730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTP-730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTP-730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTP-730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTP-730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for CTP-730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for CTP-730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for CTP-730
Study: NCT02702141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGN-CD19B
Description: Given intravenously Day 1 of 28-day or 42-day cycles
Study: NCT04892992

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DFG

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DFG
Study: NCT01065064

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RESTOR IOL
Description: The U.S. Food and Drug Administration (FDA) has granted approval of Alcon's AcrySof® ReSTOR® intraocular lens (IOL) for cataract patients with and without presbyopia. This innovative lens uses a revolutionary apodized diffractive technology to give patients a full range of quality vision (near, intermediate and distance) that greatly increases their independence from glasses after surgery
Study: NCT02107950

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DCVAC/OvCa in parallel with chemotherapy
Description: DCVAC/OvCa is the experimental therapy added on to Carboplatin and Gemcitabine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Carboplatin and Gemcitabine is Standard of Care First Line Chemotherapy
Study: NCT01403506

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-acetyl Cysteine
Description: 600 mg N-acetyl Cysteine 6 hrs before renal transplantation, and 12 hrs and 18 hrs after renal transplantation.
Study: NCT03875976

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fast Track Protocol
Description: Fast Track Care consists in educational preoperative preparation for patients, particular strategies for controlling pain and intensive early rehabilitation protocol

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care Protocol
Description: Standard Care Protocol consists in the same surgical intervention without educational preoperative preparation for patients and intensive early rehabilitation protocol
Study: NCT02414802

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: a manual spiral thrombus broken suction device
Description: A manual spiral thrombus broken suction device will be used for thrombectomy before catheter-directed thrombolysis

Intervention type: PROCEDURE
Group type: OTHER
Intervention: catheter-directed thrombolysis
Description: catheter-directed thrombolysis will be used in both arms